Implications of Cytochrome P450 Genetic Polymorphisms on the Toxicity of Antitumor Agents

Therapeutic Drug Monitoring

Volumn 26, Issue 2, 2004, Pages 236-240

  Van Schaik, Ron H N ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer therapy; Cytochrome P450; Pharmacogenetics

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 3A5; DOCETAXEL; DOXORUBICIN; ENZYME; ETOPOSIDE; FLUTAMIDE; IFOSFAMIDE; IRINOTECAN; METHOTREXATE; PACLITAXEL; TAMOXIFEN; TENIPOSIDE; VINBLASTINE; VINCRISTINE; VINDESINE;

CANCER; CONFERENCE PAPER; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FAMILY; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; HUMANS; NEOPLASMS; POLYMORPHISM, GENETIC;

EID: 16544383308     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200404000-00027     Document Type: Conference Paper

References (39)

1. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29:601-605.
2. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics. 2002;12:555-558.
3. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43-47.
4. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414-423.
5. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of debrisoquine in man. Lancet. 1977;2:584-586.
6. Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331:442-446.
7. Skoda RC, Gonzalez FJ, Demierre A, et al. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA. 1988;85:5240-5243.
8. Oscarson M. homepage of the cytochrome P450 (CYP) allele nomenclature committee. February 1, 2001. Available at: http://www.imm.ki.se/CYPalleles/. Accessed Sept 1, 2003.
9. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA. 1993;90:11825-11829.
10. Gaedigk A, Gotschall RR, Forbes NS, et al. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999;9:669-682.
11. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76-89.
12. Tateishi T, Chida M, Ariyoshi N, et al. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999;65:570-575.
13. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res. 1997;57:3402-3406.
14. Dai D, Zeldin DC, Blaisdell JA, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics. 2001;11:597-607.
15. Bahadur N, Leathart JB, Mutch E, et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol. 2002;64:1579-1589.
16. Soyama A. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet. 2002;17:374-377.
17. Soyama A, Hanioka N, Saito Y, et al. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol Toxicol. 2002;91:174-178.
18. Sonnichsen DS, Liu Q, Schuetz EG, et al. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther. 1995;275:566-575.
19. Lang T, Klein K, Fischer J, et al. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics. 2001;11:399-415.
20. Xie HJ, Yasar U, Lundgren S, et al. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003;3:53-61.
21. Hiratsuka M, Takekuma Y, Endo N, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol. 2002;58:417-421.
22. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res. 2001;7:2182-2194.
23. Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst. 2002;94:1247-1249.
24. Kehrer DF, Mathijssen RH, Verweij J, et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol. 2002;20:3122-3129.
25. Ozdemir V, Kalowa W, Tang BK, et al. Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics. 2000;10:373-388.
26. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1998;90:1225-1229.
27. Lamba JK, Lin YS, Schuetz EG, et al. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev. 2002;54:1271-1294.
28. Walker AH, Jaffe JM, Gunasegaram S, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online. Hum Mutat. 1998;12:289.
29. Amirimani B, Walker AH, Weber BL, et al. Response: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst. 1999;91:1588-1590.
30. Sata F, Sapone A, Elizondo G, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther. 2000;67:48-56.
31. Cavaco I, Gil JP, Gil-Berglund E, et al. CYP3A4 and MDR1 alleles in a Portuguese population. Clin Chem Lab Med. 2003;41:1345-1350.
32. van Schaik RHN, de Wildt SN, Brosens R, et al. The CYP3A4*3 allele: is it really rare? Clin Chem. 2001;47:1104-1106.
33. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther. 2001;299:825-831.
34. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos. 2001;29:268-273.
35. van Schaik RHN, van der Werf M, van der Heiden IP, et al. CYP3A4, CYP3A5 and MDR-1 variant alleles in the Dutch Caucasian population. Clin Pharmacol Ther. 2003;73:42.
36. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet. 2001;27:383-391.
37. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773-779.
38. van Schaik RHN, van der Heiden IP, van den Anker JN, et al. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem. 2002;48:1668-1671.
39. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5 and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine A and tacrolimus. Clin Pharmacol Ther. 2003;74:245-254.